Menu Search
Equities

Nxera Pharma Co Ltd

4565:TYO

Nxera Pharma Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)1,197.00
  • Today's Change5.00 / 0.42%
  • Shares traded470.70k
  • 1 Year change-24.76%
  • Beta1.2643
Data delayed at least 20 minutes, as of Nov 08 2024 06:30 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 16-Nov-23
  • 15-Aug-24
  • 19-Sep-24
  • 17-Oct-24
  • 07-Nov-24
Select bar for recommendation details.
Recommendations07-Nov-24
Buy2
Outperform6
Hold2
Sell0
Strong Sell0

Share price forecast in JPY

The 10 analysts offering 12 month price targets for Nxera Pharma Co Ltd have a median target of 1,850.00, with a high estimate of 3,900.00 and a low estimate of 1,300.00. The median estimate represents a 54.55% increase from the last price of 1,197.00.
High225.8%3,900.00
Med54.6%1,850.00
Low8.6%1,300.00

Earnings history & estimates in JPY

On Nov 01, 2024, Nxera Pharma Co Ltd reported 3rd quarter 2024 earnings of 13.45 per share. This result exceeded the -41.01 consensus loss of the 2 analysts covering the company and outperformed last year's 3rd quarter results by 73.37.
The next earnings announcement is expected on Feb 11, 2025.
Average growth rate-489.59%
Nxera Pharma Co Ltd reported annual 2023 losses of -87.18 per share on Feb 13, 2024.
Average growth rate-29.51%
More ▼

Revenue history & estimates in JPY

Sosei Group Corporation had 3rd quarter 2024 revenues of 9.26m. This missed the 10.42m consensus estimate of the 4 analysts following the company. This was 882.29% above the prior year's 3rd quarter results.
Average growth rate+43.11%
Sosei Group Corporation had revenues for the full year 2023 of 12.77m. This was 18.00% below the prior year's results.
Average growth rate+15.28%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.